Seagen has described new antibody-drug conjugates (ADCs) comprising antibodies covalently bound to stimulator of interferon genes protein (STING; TMEM173) agonists through a linker and reported to be useful for the treatment of cancer.

Scripps Research Institute and Vova Ida Therapeutics have divulged novel compounds that may inhibit NAD consumption and/or increase NAD synthesis, reported to be useful for neurodegenerative, degenerative and metabolic disorders, including amyotrophic lateral sclerosis, diabetes, nonalcoholic fatty liver disease (NAFLD), Parkinson's disease and renal, metabolic and retinal diseases, among other disorders.

Alexion Pharmaceuticals has synthesized new macrocycle compounds acting as complement factor B inhibitors reported to be useful for the treatment of age-related macular degeneration, multiple sclerosis, rheumatoid arthritis, retinal degeneration, chronic obstructive pulmonary disease (COPD), paroxysmal nocturnal hemoglobinuria and cardiovascular disorders.

Schroedinger has patented fused heterocycles acting as Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.

WuXi Biologics (Shanghai) and WuXi Biologics Ireland have divulged antibody-drug conjugates (ADCs) comprising anti-TROP2 antibodies covalently linked to cytotoxic drugs via linker reported to be useful for the treatment of cancer.

RP Scherer Technologies has synthesized new antibody-drug conjugates (ADCs) comprising camptothecine or camptothecine derivatives linked to a polypeptide such as an antibody through a linker reported to be useful for the treatment of cancer.

Vellore Institute of Technology University (VIT) and BG Negev Technologies and Applications have described new curcumin or piperine analogues acting as NF-kappaB (NFKB) activation inhibitors and/or quorum sensing signaling inhibitors reported to be useful for treatment of cancer, fungal and bacterial infections and inflammatory disorders.

Beckley Psytech has divulged ergoline analogues acting as 5-HT2A and/or 5-HT2B and/or 5-HT2C receptor agonists reported to be useful for the treatment of depression.

Chengdu Baiyu Pharmaceutical has presented pyrimidine derivatives acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer.

Monte Rosa Therapeutics has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety reported to be useful for the treatment of cancer.